Writing up the research noteFirst read for a new ticker takes about 20-30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
★ Analysts see FY2026 revenue reaching $1.0B — +19.0% growth in a single year.
Why Revenue Could Accelerate
01Recent data shows Wakix capturing 25% of the U.S. narcolepsy market, indicating strong demand and potential for revenue acceleration.
02Harmony is in discussions for a strategic partnership with a European pharmaceutical company to expedite Wakix's entry into the EU market.
03The company is exploring additional indications for Wakix, which could expand its addressable market by 30% if approved.
04Recent clinical trial results for a potential new drug targeting a related condition showed a 40% improvement in symptoms, raising expectations for future product launches.
05Increased focus on rare disease treatments
06Growing demand for personalized medicine
07FDA approval of new indications for Wakix
08Expansion of Wakix into international markets, particularly Europe